BioCentury | Aug 21, 2020
Finance

CF Foundation’s Longwood incubator fund to push early tech toward CF

The Cystic Fibrosis Foundation’s partnership with Longwood Fund aims to instill CF research as a priority in start-ups built around new technologies. If successful, the charity is hoping to partner with other VCs to broaden...
BioCentury | Jun 4, 2020
Product Development

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

Newly presented Phase III data burnish GSK’s case for a regulatory submission planned for this month seeking to expand the label of lupus drug Benlysta to include lupus nephritis. Richard Furie, the lead investigator of...
BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Inhibiting AFF4 and CDK9, components of the transcription-regulating super elongation complex, could treat diffuse midline glioma. In human diffuse midline glioma cell lines, shRNAs targeting AFF4 or CDK9 or...
BioCentury | Feb 12, 2020
Finance

AurorA debuts to back early-stage European biotechs

A new Europe-focused investment vehicle has launched with €10 million in backing from two Italian biopharmas. AurorA Science will be managed by AurorA-TT, a tech transfer company founded in 2017 and led by co-founder, Chairman...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

Inscripta raises $125M series D Inscripta Inc. raised $125 million in a series D round led by existing investor Paladin Capital, bringing the total capital raised by the company to $260 million since 2015. New...
BioCentury | Dec 5, 2019
Company News

Dec. 4 Company Quick Takes: Allakos on the block?; plus Aurinia, Tecentriq, Gatehouse-AZ, Novartis-Amazon, Merck KGaA-Ping An and ICT

Allakos shares jump on report of potential sale Allakos Inc. (NASDAQ:ALLK) declined to comment on a Bloomberg report citing unnamed sources that the company has hired a financial adviser to explore strategic options, including a...
BioCentury | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

ChemoCentryx became the latest biotech to post a triple-digit percentage gain based on a clinical readout, adding more than $1.3 billion in market cap after its avacopan showed statistical superiority to standard-of-care therapy in a...
BioCentury | Sep 12, 2019
Distillery Therapeutics

A mAb blocking IL-1 co-receptor for inflammatory, autoimmune diseases

DISEASE CATEGORY: Inflammation; autoimmune disease INDICATION: Inflammation; allergy; psoriasis A mAb against the IL-1 family co-receptor IL1RAP could treat peritonitis, allergic airway inflammation and psoriasis. The anti-IL1RAP mAb, which has an Fc domain mutated to...
BioCentury | Jul 26, 2019
Emerging Company Profile

Limbix: A virtual treatment for the reality of depression

Limbix is using virtual reality to treat mental health conditions, starting with adolescent depression, where it could offer an alternative to medicating kids and the long wait lists for therapists. The company launched in 2016...
Items per page:
1 - 10 of 791